Banner Publications MH200828 N141

Publications

Results found: 192

Showing results: 1 - 50

Nature medicine

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.

01-12-2020
Key
Annals of oncology : official journal of the European Society for Medical Oncology

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.

15-06-2022
Clinica chimica acta; international journal of clinical chemistry

Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.

13-06-2022
Melanoma research

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.

06-06-2022
Annals of surgical oncology

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).

01-06-2022
Nature medicine

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.

01-06-2022
Journal of translational medicine

The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.

10-05-2022
European journal of cancer (Oxford, England : 1990)

Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study.

01-05-2022
British journal of cancer

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.

01-05-2022
Science translational medicine

Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors.

27-04-2022
Annals of surgical oncology

Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).

15-04-2022
European journal of cancer (Oxford, England : 1990)

Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

01-04-2022
Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.

01-04-2022
JAMA surgery

Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma.

01-04-2022
International journal of cancer

The unfavorable effects of COVID-19 on Dutch advanced melanoma care.

01-03-2022
Trials

Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.

13-02-2022
European journal of cancer (Oxford, England : 1990)

Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.

01-02-2022
Journal of the European Academy of Dermatology and Venereology : JEADV

Survival of stage IV melanoma in Belgium and the Netherlands.

01-02-2022
Annals of oncology : official journal of the European Society for Medical Oncology

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.

01-02-2022
Cancer cell

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.

10-01-2022
European urology open science

Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment.

01-01-2022
Nature communications

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.

22-12-2021
Current oncology (Toronto, Ont.)

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors.

20-12-2021
The Lancet. Oncology

mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial.

01-12-2021
European journal of cancer (Oxford, England : 1990)

Adjuvant treatment for melanoma in clinical practice - Trial versus reality.

01-11-2021
BJU international

Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial.

27-10-2021
Proceedings of the National Academy of Sciences of the United States of America

Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.

26-10-2021
European journal of cancer (Oxford, England : 1990)

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.

18-10-2021
Cancers

Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands.

11-10-2021
Clinical cancer research : an official journal of the American Association for Cancer Research

Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4.

01-10-2021
Cancer immunology, immunotherapy : CII

Metabolic profiles of regulatory T cells in the tumour microenvironment.

01-09-2021
Annals of surgery

Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial.

01-08-2021
The American Journal of dermatopathology

Letter Regarding Editorial by Samuel Zagarella.

01-07-2021
European journal of cancer (Oxford, England : 1990)

Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!

01-07-2021
Annals of oncology : official journal of the European Society for Medical Oncology

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.

01-07-2021
European journal of cancer (Oxford, England : 1990)

The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.

01-07-2021
Nature medicine

An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer.

01-07-2021
Journal of translational medicine

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy).

30-06-2021
Cancers

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors.

05-06-2021
The Lancet. Oncology

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.

01-06-2021
Annals of oncology : official journal of the European Society for Medical Oncology

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.

01-06-2021
The Lancet. Oncology

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.

01-05-2021
Annals of internal medicine

Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.

01-05-2021
European journal of cancer (Oxford, England : 1990)

Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.

01-05-2021
The Lancet. Oncology

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

01-05-2021
British journal of cancer

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.

01-05-2021
Nature medicine

COVID-19 vaccination: the VOICE for patients with cancer.

01-04-2021
Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Reply to E. Hindié.

10-03-2021
British journal of cancer

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.

01-03-2021
British journal of cancer

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.

01-02-2021

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.